Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

09 févr. 2021 07h00 HE | Source: Melt Pharmaceuticals; Harrow Health, Inc.

Melt Pharmaceuticals Completes Phase 1 Study for Sublingual, Non-Opioid Pain and Sedation Drug Candidate

BOSTON, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing first-in-class medicines for sedation and analgesia, announced results from...
29 juil. 2020 07h00 HE | Source: Melt Pharmaceuticals

Melt Pharmaceuticals Enters the Clinical Stage of MELT-100 Development

FDA has accepted MELT-100 IND; Phase 1 study enrollment to start immediately BOSTON, July 29, 2020 (GLOBE NEWSWIRE) -- Melt Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing...
13 févr. 2019 07h00 HE | Source: Harrow Health, Inc.; Melt Pharmaceuticals

Melt Pharmaceuticals Improves Patent Estate for Sublingual Non-Opioid Pain and Sedation Formulations

SAN DIEGO and BOSTON, Feb. 13, 2019 (GLOBE NEWSWIRE) -- Melt Pharmaceuticals, Inc., a specialty pharmaceutical company recently deconsolidated from Harrow Health, Inc. (NASDAQ: HROW), today...
05 févr. 2019 07h00 HE | Source: Harrow Health, Inc.; Melt Pharmaceuticals, Inc.

Harrow Health Announces $11 Million Series A Financing for Melt Pharmaceuticals Subsidiary

SAN DIEGO and BOSTON, Feb. 05, 2019 (GLOBE NEWSWIRE) -- Melt Pharmaceuticals, Inc., an affiliated company of Harrow Health, Inc. (NASDAQ: HROW), today announced it has entered into definitive stock...